Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning.

Medicare and Medicaid would be required to cover weight loss drug prescriptions for millions of obese Americans under plans announced by the Biden administration Tuesday.

“I love Thanksgiving for the pumpkin pie — it's such a low-sugar dessert that it tends to be fine for your blood sugar,” Bensley tells PEOPLE. “Chocolate is okay, but just try to do it with your meal to keep that blood sugar stable.”

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.

The diabetes drug, Ozempic, has been in the headlines, causing quite a stir. Senior writer for Drugwatch.com, Terry Turner, joined LiveNow to discuss how some people are ending up in the hospital, for misusing Ozempic as a weight loss drug.

The plan would need to be supported by the incoming Trump administration, which has vowed to cut costs across the federal government.